866-997-4948(US-Canada Toll Free)

Pear Therapeutics Inc - Product Pipeline Analysis, 2018 Update

Published By :

GlobalData

Published Date : Dec 2018

Category :

Pharmaceutical

No. of Pages : 37 Pages

Summary

Pear Therapeutics Inc (Pear Therapeutics) develops software-based prescription digital therapeutics for the treatment of severe medical conditions and diseases. Its product pipeline includes reSET-O for treating opioid use disorder (OUD) in conjunction with opioid replacement therapy; Thrive designed for schizophrenia; reCALL using virtual reality exposure therapy to treat combat posttraumatic stress disorder (PTSD); reVIVE against general anxiety disorder; and PEAR-005 to PEAR-011 for treating pain, major depressive disorder, insomnia, Parkinson's disease and inflammatory conditions. Pear Therapeutics reSET, is an FDA-authorized prescription therapeutic for substance use disorder (SUD) used as an outpatient treatment. The company works in partnership with Center for Technology and Behavioral Health, Dartmouth College, Ehave, Inc., Intellectual Ventures Management LLC, Novartis AG, and others. Pear Therapeutics is headquartered in Boston, Massachusetts, the US.

This report is a source for data, analysis, and actionable intelligence on the companys portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Pear Therapeutics Inc
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note: Some sections may be missing if data is unavailable for the company
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Pear Therapeutics Inc Company Overview 5
Pear Therapeutics Inc Company Snapshot 5
Pear Therapeutics Inc Pipeline Products and Ongoing Clinical Trials Overview 5
Pear Therapeutics Inc Pipeline Analysis Overview 8
Pear Therapeutics Inc - Key Facts 8
Pear Therapeutics Inc - Major Products and Services 9
Pear Therapeutics Inc Pipeline Products by Development Stage 11
Pear Therapeutics Inc Ongoing Clinical Trials by Trial Status 13
Pear Therapeutics Inc Pipeline Products Overview 15
Digital Therapeutic - Inflammatory conditions 15
Digital Therapeutic - Inflammatory conditions Product Overview 15
Digital Therapeutic - Major Depressive Disorder 16
Digital Therapeutic - Major Depressive Disorder Product Overview 16
Digital Therapeutic - Oncology 17
Digital Therapeutic - Oncology Product Overview 17
Digital Therapeutic - Parkinson's Disease 18
Digital Therapeutic - Parkinson's Disease Product Overview 18
Digital Therapeutic - Respiratory 19
Digital Therapeutic - Respiratory Product Overview 19
PEAR-003 - Insomnia 20
PEAR-003 - Insomnia Product Overview 20
PEAR-006 - Multiple Sclerosis 21
PEAR-006 - Multiple Sclerosis Product Overview 21
reCALL 22
reCALL Product Overview 22
reVIVE 23
reVIVE Product Overview 23
Thrive 24
Thrive Product Overview 24
Thrive Clinical Trial 25
Pear Therapeutics Inc - Key Competitors 26
Pear Therapeutics Inc - Key Employees 27
Pear Therapeutics Inc - Locations And Subsidiaries 28
Head Office 28
Other Locations & Subsidiaries 28
Recent Developments 29
Pear Therapeutics Inc, Recent Developments 29
Jan 16, 2018: Magellan Health Continues Innovation and Efforts to Improve Outcomes for Patients with Substance Use Disorder 29
Dec 12, 2017: Pear Therapeutics Wins Fierce Innovation Life Science Award for reSET Prescription Digital Therapeutic 29
Oct 18, 2017: Pear Therapeutics Receives Expedited Access Pathway Designation from FDA for reSET-O Prescription Digital Therapeutic to Treat Opioid Use Disorder 30
Sep 26, 2017: Pear Therapeutics Selected to Participate in the FDAs Digital Health Software Pre-Cert Pilot Program 30
Sep 14, 2017: FDA permits marketing of mobile medical application for substance use disorder 31
Sep 14, 2017: Pear Therapeutics Obtains FDA Clearance Of The First Prescription Digital Therapeutic To Treat Disease 31
Jul 11, 2017: Enhancing Digital Medicine to Tackle Addiction 32
Aug 25, 2016: The Largest and Longest Study of Patients with Schizophrenia Interacting with Digital Therapeutics Results Released 33
Appendix 34
Methodology 34
About GlobalData 37
Contact Us 37
Disclaimer 37

List of Tables
Pear Therapeutics Inc Pipeline Products and Ongoing Clinical Trials Overview 5
Pear Therapeutics Inc Pipeline Products by Equipment Type 6
Pear Therapeutics Inc Pipeline Products by Indication 7
Pear Therapeutics Inc Ongoing Clinical Trials by Trial Status 7
Pear Therapeutics Inc, Key Facts 8
Pear Therapeutics Inc, Major Products and Services 9
Pear Therapeutics Inc Number of Pipeline Products by Development Stage 11
Pear Therapeutics Inc Pipeline Products Summary by Development Stage 12
Pear Therapeutics Inc Ongoing Clinical Trials by Trial Status 13
Pear Therapeutics Inc Ongoing Clinical Trials Summary 14
Digital Therapeutic - Inflammatory conditions - Product Status 15
Digital Therapeutic - Inflammatory conditions - Product Description 15
Digital Therapeutic - Major Depressive Disorder - Product Status 16
Digital Therapeutic - Major Depressive Disorder - Product Description 16
Digital Therapeutic - Oncology - Product Status 17
Digital Therapeutic - Oncology - Product Description 17
Digital Therapeutic - Parkinson's Disease - Product Status 18
Digital Therapeutic - Parkinson's Disease - Product Description 18
Digital Therapeutic - Respiratory - Product Status 19
Digital Therapeutic - Respiratory - Product Description 19
PEAR-003 - Insomnia - Product Status 20
PEAR-003 - Insomnia - Product Description 20
PEAR-006 - Multiple Sclerosis - Product Status 21
PEAR-006 - Multiple Sclerosis - Product Description 21
reCALL - Product Status 22
reCALL - Product Description 22
reVIVE - Product Status 23
reVIVE - Product Description 23
Thrive - Product Status 24
Thrive - Product Description 24
Thrive - A Randomized, Sham-controlled Study of PEAR-004 as an Adjunct to Standard-of-care Treatment for Schizophrenia 25
Pear Therapeutics Inc, Key Employees 27
Pear Therapeutics Inc, Other Locations 28
Glossary 36

List of Figures
Pear Therapeutics Inc Pipeline Products by Equipment Type 6
Pear Therapeutics Inc Pipeline Products by Development Stage 11
Pear Therapeutics Inc Ongoing Clinical Trials by Trial Status 13

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *